However, the prognostic power of CDX2 in this overall screening approach was considerably lower than those of the different CRC subtypes, WHO grade and tumour budding, which all showed stronger discrimination of survival groups than CDX2 expression, generally picturing the aforementioned WHO parameters as superior prognostic biomarkers in unselected CRC cohorts. The gene discussed is CDX2; the disease is colorectal carcinoma.